Kineticos Ventures
Kineticos is Joining the Fight Against Antimicrobial Resistance
Antimicrobial Resistance (“AMR”) has been increasing globally over the past few decades leading to an increase in mortality and morbidity, surgical intervention, amputation, disfigurement, and prolonged hospital stays, affecting both developed and developing countries. Kineticos aims to support the development of therapeutic (including novel anti-biotics and anti-fungals), service, vaccine, and diagnostic companies. Kineticos intends to invest in companies with disruptive technologies to bring their innovations to market and address other solutions for the growing burden of AMR.
AMR represents a major challenge in the ability to treat infectious diseases. In the U.S. more than 2.80 million drug-resistant infections occurred and were responsible for 35,000 deaths in 2019. Globally, it is estimated that 4.95 million deaths were associated with bacterial AMR. This number includes 1.27 million deaths directly caused by resistant bacteria. Despite the huge global burden, in the past 35 years, only one new chemical entity (NCE) has been approved by the FDA. Kineticos plans to collaborate with leading investors and other organizations aligned in the support of early-stage biotechs across all segments of AMR (diagnostics, services, therapeutics, and vaccines). The focus will be on targeting indications with the highest unmet medical needs and top-priority pathogens defined by the WHO and CDC.
Here is a must-watch documentary on the global fight against antimicrobial resistance!
Clinical Trials
~50 new antibiotics in clinical development
Global Burden
10M Deaths Globally p.a. and $100T of lost output by 2050 (WHO)
Market
$14B+ market size in 2021 with a 5%+ CAGR
Additional Resources
For a deeper understanding of the science behind AMR and to stay up to date with current trends, explore some of our highly recommended articles listed below.
Funding and Support for AMR Companies
https://gardp.org/
Overview of AMR
https://antimicrobialresistancefighters.org/
https://www.usp.org/antimicrobial-resistance
https://www.nature.com/immersive/d41591-023-00043-5/index.html
https://www.bu.edu/articles/2022/can-we-prevent-antibiotic-resistance/
Health Organizations
https://www.nhsinform.scot/campaigns/antimicrobial-resistance-amr
https://www.cdc.gov/drugresistance/index.html
https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
Phage Therapy
https://www.nature.com/articles/d41586-023-02209-0
Policy
History of Antibiotic Development